Compounds > triciribine
Page last updated: 2024-08-24

triciribine and Breast Neoplasms

triciribine has been researched along with Breast Neoplasms in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Casey, PJ; Tang, J; Wang, M1
Cheng, JQ; Coppola, D; Guo, JP1
Kim, RJ; Kim, SR; Lee, SY; Lee, YK; Nam, JS; Park, JR; Roh, KJ1
Adler, AS; Chang, HY; Chou, J; Collins, CC; Dijkgraaf, GJ; Gray, JW; Griffith, OL; Huang, G; Korkola, JE; Kouros-Mehr, H; Krig, SR; Lawson, DA; Littlepage, LE; Qu, K; Rugo, HS; Sternlicht, MD; Sweeney, CA; Werb, Z; Xue, Q; Yaswen, P1
Brady, SW; Ge, H; Hortobagyi, GN; Jaffee, EM; Li, P; Li, SH; Muller, WJ; Sahin, O; Wang, H; Wang, Q; Xiao, Y; Yu, D1
Brychtova, V; Fabian, P; Hrstka, R; Hupp, TR; Murray, E; Vojtesek, B1
Esparza, L; Fraschini, G; Frye, D; Hoffman, K; Holmes, FA; Hortobagyi, GN; Newman, RA; Raber, MN1

Trials

1 trial(s) available for triciribine and Breast Neoplasms

ArticleYear
Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer.
    Cancer chemotherapy and pharmacology, 1996, Volume: 37, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Ribonucleosides; Treatment Outcome

1996

Other Studies

6 other study(ies) available for triciribine and Breast Neoplasms

ArticleYear
Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair.
    Life science alliance, 2021, Volume: 4, Issue:12

    Topics: Animals; Apoptosis; Benzamides; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Repair; Female; Genetic Vectors; HEK293 Cells; Humans; Indazoles; MAP Kinase Signaling System; Mice; Mice, SCID; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Protein Methyltransferases; Ribonucleosides; RNA, Small Interfering; Tumor Burden; Xenograft Model Antitumor Assays

2021
IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.
    The Journal of biological chemistry, 2011, Oct-28, Volume: 286, Issue:43

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Enzyme Activation; Female; Gene Deletion; HEK293 Cells; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Kinase; Mammary Neoplasms, Animal; Mice; Mice, Knockout; NIH 3T3 Cells; Oxadiazoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphorylcholine; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Ribonucleosides; Trans-Activators; Transcription Factors

2011
Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation.
    Cancer science, 2012, Volume: 103, Issue:7

    Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Ion Channels; MCF-7 Cells; Membrane Glycoproteins; Microfilament Proteins; Neoplasm Proteins; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleosides; RNA Interference

2012
The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.
    Cancer discovery, 2012, Volume: 2, Issue:7

    Topics: Animals; Antibiotics, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Neoplastic Stem Cells; NIH 3T3 Cells; Oligonucleotide Array Sequence Analysis; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleosides; Survival Analysis; Trans-Activators; Xenograft Model Antitumor Assays

2012
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.
    Cancer research, 2012, Sep-01, Volume: 72, Issue:17

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line; CTLA-4 Antigen; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Female; Gene Expression; Humans; Interferon-gamma; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Transgenic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptor, ErbB-2; Ribonucleosides; T-Lymphocytes; Trastuzumab; Tumor Microenvironment

2012
Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2.
    Cancer letters, 2013, Jun-10, Volume: 333, Issue:2

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antineoplastic Agents, Hormonal; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Female; Humans; MicroRNAs; Molecular Sequence Data; Mucoproteins; Oncogene Proteins; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins c-akt; Ribonucleosides; Serine; Signal Transduction; Tamoxifen

2013